Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting.

Biologic-experienced and biologic-naive patients with psoriasis who initiated and maintained secukinumab treatment reported improvements in PROs at 6-month and/or 12-month follow-up visits. These findings suggest that secukinumab is a potential biologic for psoriasis at any point along the patient treatment journey.